Asset profile
Blinatumomab
Multispecific antibody
Approvedregulatory verdict
Evidence outlook
Approved: CD19-positive B-cell precursor acute lymphoblastic leukaemia (FDA)
This approval is for an indication outside this terminal's covered markets; the covered program shown here is investigational. Regulatory approval supersedes design-level evidence grading for the approved use.
Also in development:Systemic Lupus Erythematosus · Phase 2
Also approved:US: CD19-positive B-cell precursor acute lymphoblastic leukaemia, outside this platform's coverage
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
104 competitors in this universe: 2 direct rivals (same mechanism and indication), 0 same-class, 102 same-indication; 30 further along in development.
Unlock with Research ↗
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Blinatumomab: this drug | Phase 3 | Multispecific antibody | CD19 x CD3 | ||
| Surovatamig | Phase 3 | Multispecific antibody | CD19 x CD3 | ||
| CLN-978 | Phase 1 | — | CD19 x CD3 | ||
| Abatacept (Orencia) | Approved | Protein / enzyme therapeutic | CD80/CD86 (CTLA-4-Ig), Selective T Cell Costimulation Modulator, CD80/CD86 (B7-1/B7-2) on antigen-presenting cells | ||
| Adalimumab (Humira) | Approved | Monoclonal antibody | TNF-alpha | ||
| Adalimumab-Adbm (Cyltezo) | Approved | Monoclonal antibody | TNF-alpha | ||
| Adalimumab-Ryvk (Simlandi) | Approved | — | TNF-alpha | ||
| Aldesleukin (Proleukin) | Approved | Recombinant Cytokine (il-2) | Interleukin-2 receptor (IL-2R) | ||
| Anakinra (r-metHuIL-1ra) | Approved | Protein / enzyme therapeutic | Interleukin-1 receptor (IL-1R), Interleukin-1 receptor type 1 (IL-1R1) | ||
| Anifrolumab | Approved | Monoclonal antibody | Type I interferon receptor, Type I interferon receptor subunit 1 (IFNAR1) | ||
| Avacopan (Tavneos) | Approved | Small molecule | Complement C5a receptor 1 (C5aR1/CD88) | ||
| Baricitinib (Olumiant) | Approved | Small molecule | JAK, JAK1/2 | ||
| Belimumab (GSK1550188) | Approved | Monoclonal antibody | BAFF / BLyS (B-lymphocyte stimulator), BAFF (BLyS) | ||
| Certolizumab Pegol (Cimzia) | Approved | Antibody fragment | TNF-alpha | ||
| CT-P13 (Inflectra / Remsima) | Approved | Monoclonal antibody | TNF-alpha | ||
| CT-P47 (tocilizumab) (Avtozma) | Approved | Monoclonal antibody | IL-6R antagonist |
…and 89 more. Research shows the complete landscape.
Research
Unlock with Research ↗Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(76 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (7)
October 2026 (2)
Phase 1/2Acute Lymphoblastic Leukemia, B-cell Non Hodgkin Lymphoma, Pre B-Cell Acute Lymphoblastic LeukaemiaActive not recruiting
Est. primary completion 2026-10-30 · NCT03114865 · CT.gov ↗
What to watch
Phase 2Acute Lymphoblastic Leukemia, Adult B-CellActive not recruiting
Est. primary completion 2026-10-30 · NCT03709719 · CT.gov ↗
What to watch
November 2026 (3)
Phase 1B-cell Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia (CML) in Lymphoid Blast Crisis …Recruiting
Est. primary completion 2026-11-01 · NCT03595917 · CT.gov ↗
What to watch
Phase 2Acute Lymphoblastic LeukemiaRecruiting
Est. primary completion 2026-11-01 · NCT05519579 · CT.gov ↗
What to watch
Phase 2B Acute Lymphoblastic Leukemia, B Lymphoblastic LymphomaRecruiting
Est. primary completion 2026-11-01 · NCT02877303 · CT.gov ↗
What to watch
2027 (25)
January 2027 (1)
Phase 2Acute Lymphoblastic Leukemia, Measurable Residual Disease (MRD)Recruiting
Est. primary completion 2027-01 · NCT06886074 · CT.gov ↗
What to watch
February 2027 (3)
Phase 2B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, Recurrent B Acute Lymphoblastic Leukemia …Recruiting
Est. primary completion 2027-02-01 · NCT03739814 · CT.gov ↗
What to watch
Early phase / not applicableAcute Lymphoblastic Leukemia, B-precursorRecruiting
Est. primary completion 2027-02-05 · NCT07003737 · CT.gov ↗
What to watch
Phase 2Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia With BCR-ABL1 …Active not recruiting
Est. primary completion 2027-02-28 · NCT03147612 · CT.gov ↗
What to watch
March 2027 (1)
Phase 2Acute Lymphoblastic Leukemia, Philadelphia Chromosome-PositiveActive not recruiting
Est. primary completion 2027-03 · NCT04329325 · CT.gov ↗
What to watch
May 2027 (1)
Phase 1/2Philadelphia Chromosome-Positive, Acute Lymphoblastic LeukemiaRecruiting
Est. primary completion 2027-05-01 · NCT06308588 · CT.gov ↗
What to watch
June 2027 (1)
Phase 2B-Cell Acute Lymphoblastic Leukemia, AdultActive not recruiting
Est. primary completion 2027-06-01 · NCT07199855 · CT.gov ↗
What to watch
September 2027 (3)
Phase 3Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive), ALL, Adult, Philadelphia-Positive ALLActive not recruiting
Est. primary completion 2027-09 · NCT04722848 · CT.gov ↗
What to watch
Phase 3Acute Lymphoblastic Leukemia, Mixed Phenotype Acute LeukemiaRecruiting
Est. primary completion 2027-09 · NCT05327894 · CT.gov ↗
What to watch
Phase 3B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Down SyndromeActive not recruiting
Est. primary completion 2027-09-30 · NCT03914625 · CT.gov ↗
What to watch
October 2027 (1)
Phase 3Precursor B-cell Acute Lymphoblastic LeukemiaNot yet recruiting
Est. primary completion 2027-10-10 · NCT07723911 · CT.gov ↗
What to watch
November 2027 (3)
Phase 2Acute Lymphoid Leukemia (ALL)Not yet recruiting
Est. primary completion 2027-11-01 · NCT06930105 · CT.gov ↗
What to watch
Phase 1/2B Cell Precursor Acute Lymphoblastic LeukemiaActive not recruiting
Est. primary completion 2027-11-24 · NCT04521231 · CT.gov ↗
What to watch
Phase 2Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, BCR-ABL1 Fusion Protein Expression …Recruiting
Est. primary completion 2027-11-30 · NCT03263572 · CT.gov ↗
What to watch
December 2027 (11)
Phase 1B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Mixed Phenotype Acute Leukemia …Active not recruiting
Est. primary completion 2027-12-02 · NCT04872790 · CT.gov ↗
What to watch
Phase 1Systemic Lupus ErythematosusRecruiting
Est. primary completion 2027-12-07 · NCT06789107 · CT.gov ↗
What to watch
Phase 1/2B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative …Recruiting
Est. primary completion 2027-12-25 · NCT01371630 · CT.gov ↗
What to watch
Phase 1ABO Blood Type Incompatible Kidney TransplantationNot yet recruiting
Est. primary completion 2027-12-31 · NCT07706205 · CT.gov ↗
What to watch
Phase 2Newly Diagnosed Mixed Phenotype Acute LeukemiaNot yet recruiting
Est. primary completion 2027-12-31 · NCT07573670 · CT.gov ↗
What to watch
Phase 2Acute Lymphoblastic Leukemia, Immunotherapy, Blinatumomab, Inotuzumab OzogamicinRecruiting
Est. primary completion 2027-12-31 · NCT06985485 · CT.gov ↗
What to watch
Phase 2Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+), BCR-ABL Positive Acute Lymphoblastic LeukemiaNot yet recruiting
Est. primary completion 2027-12-31 · NCT07301424 · CT.gov ↗
What to watch
Phase 2Leukemia, RelapseRecruiting
Est. primary completion 2027-12-31 · NCT07105579 · CT.gov ↗
What to watch
Phase 2B Acute Lymphoblastic Leukemia, Philadelphia Chromosome NegativeRecruiting
Est. primary completion 2027-12-31 · NCT07564453 · CT.gov ↗
What to watch
Early phase / not applicableB Cell Precursor Acute Lymphoblastic Leukemia, Pediatric, Minimal Residual Disease, Next Generation Sequencing (NGS)Not yet recruiting
Est. primary completion 2027-12-31 · NCT06763302 · CT.gov ↗
What to watch
2028 (19)
March 2028 (4)
Early phase / not applicableAcute Lymphoblastic Leukemia, AdultRecruiting
Est. primary completion 2028-03-01 · NCT07495631 · CT.gov ↗
What to watch
Early phase / not applicablePh-Like, Acute Lymphoblastic LeukemiaRecruiting
Est. primary completion 2028-03-01 · NCT07454226 · CT.gov ↗
What to watch
Phase 2/3Myasthenia GravisNot yet recruiting
Est. primary completion 2028-03-31 · NCT06836973 · CT.gov ↗
What to watch
Early phase / not applicablePh+ ALLRecruiting
Est. primary completion 2028-03-31 · NCT07493161 · CT.gov ↗
What to watch
April 2028 (1)
Phase 1B-cell Acute Lymphoblastic LeukemiaRecruiting
Est. primary completion 2028-04-01 · NCT06507514 · CT.gov ↗
What to watch
May 2028 (2)
June 2028 (2)
Phase 1Recurrent B Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic LeukemiaRecruiting
Est. primary completion 2028-06-01 · NCT07133997 · CT.gov ↗
What to watch
Phase 2Down Syndrome, Recurrent B Acute Lymphoblastic LeukemiaRecruiting
Est. primary completion 2028-06-30 · NCT04546399 · CT.gov ↗
What to watch
July 2028 (2)
August 2028 (1)
Phase 2Rheumatoid ArthritisRecruiting
Est. primary completion 2028-08-06 · NCT06570798 · CT.gov ↗
What to watch
November 2028 (1)
Phase 1ALL (Acute B-Lymphoblastic Leukemia)Recruiting
Est. primary completion 2028-11-30 · NCT07677878 · CT.gov ↗
What to watch
December 2028 (6)
Phase 1Hematologic MalignancyRecruiting
Est. primary completion 2028-12 · NCT07052370 · CT.gov ↗
What to watch
Phase 1/2Lymphoblastic LeukemiaRecruiting
Est. primary completion 2028-12 · NCT05848687 · CT.gov ↗
What to watch
Phase 1/2Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia, Minimal Residual Disease + B-Cell Acute Lymphoblastic LeukemiaActive not recruiting
Est. primary completion 2028-12-05 · NCT07134088 · CT.gov ↗
What to watch
Phase 1/2Relapsed/Refractory, B-cell Acute Lymphocytic LeukemiaRecruiting
Est. primary completion 2028-12-31 · NCT06287229 · CT.gov ↗
What to watch
Phase 2Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic LeukemiaRecruiting
Est. primary completion 2028-12-31 · NCT06317662 · CT.gov ↗
What to watch
Phase 4Autoimmune Encephalitis (AE), Autoimmune CerebellitisNot yet recruiting
Est. primary completion 2028-12-31 · NCT07686042 · CT.gov ↗
What to watch
2029 (8)
January 2029 (1)
Phase 1/2B-cell Acute Lymphoblastic Leukemia, B-Cell Acute Lymphoblastic Leukemia, Adult, B-ALLNot yet recruiting
Est. primary completion 2029-01 · NCT07313852 · CT.gov ↗
What to watch
July 2029 (1)
Phase 2Philadelphia Chromosome Positive Acute Lymphoblastic LeukemiaRecruiting
Est. primary completion 2029-07-01 · NCT06061094 · CT.gov ↗
What to watch
August 2029 (2)
Phase 2CD19 Positive, Mixed Phenotype Acute Leukemia (MPAL)Recruiting
Est. primary completion 2029-08 · NCT07222579 · CT.gov ↗
What to watch
Phase 1Blinatumomab, Revumenib, Lymphoblastic Leukemia, KMT2A-rearrangedNot yet recruiting
Est. primary completion 2029-08-31 · NCT07283640 · CT.gov ↗
What to watch
September 2029 (1)
Phase 3Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)Active not recruiting
Est. primary completion 2029-09-07 · NCT04994717 · CT.gov ↗
What to watch
December 2029 (3)
Phase 1Leukemia, Myeloid, Chronic, Myeloid Leukemia, Chronic Myeloid Leukemia, Philadelphia Positive Acute Lymphoblastic Leukemia …Recruiting
Est. primary completion 2029-12-27 · NCT04260022 · CT.gov ↗
What to watch
Phase 2/3Acute Lymphoblastic Leukemia ALL, Childhood Leukemia, Acute Lymphoblastic, B Cell Acute Lymphoblastic Leukemia (B-ALL)Recruiting
Est. primary completion 2029-12-31 · NCT06764238 · CT.gov ↗
What to watch
Phase 2/3Acute Lymphoblastic Leukemia ALL, Childhood Leukemia, Acute Lymphoblastic, B Cell Acute Lymphoblastic Leukemia (B-ALL)Recruiting
Est. primary completion 2029-12-31 · NCT06882057 · CT.gov ↗
What to watch
2030 (4)
April 2030 (1)
Early phase / not applicableAdult ALL, MPALNot yet recruiting
Est. primary completion 2030-04-01 · NCT06991920 · CT.gov ↗
What to watch
July 2030 (1)
Phase 2Acute Lymphoblastic Leukemia, Philadelphia Chromosome-Negative Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia (ALL), LeukemiaRecruiting
Est. primary completion 2030-07-31 · NCT07227584 · CT.gov ↗
What to watch
October 2030 (1)
Phase 2Phase 2 Study, Blinatumomab, Acute Lymphoblastic LeukemiaNot yet recruiting
Est. primary completion 2030-10-12 · NCT07192237 · CT.gov ↗
What to watch
December 2030 (1)
Phase 2B Acute Lymphoblastic LeukemiaRecruiting
Est. primary completion 2030-12-01 · NCT06124157 · CT.gov ↗
What to watch
2031 (6)
March 2031 (1)
Early phase / not applicableAcute Lymphoblastic LeukemiaNot yet recruiting
Est. primary completion 2031-03-06 · NCT07443592 · CT.gov ↗
What to watch
April 2031 (1)
Phase 2Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative …Not yet recruiting
Est. primary completion 2031-04-16 · NCT07636564 · CT.gov ↗
What to watch
June 2031 (1)
Phase 1/2Myeloid LeukemiaNot yet recruiting
Est. primary completion 2031-06-03 · NCT07604233 · CT.gov ↗
What to watch
September 2031 (2)
Phase 1/2B-cell Acute Lymphoblastic LeukemiaActive not recruiting
Est. primary completion 2031-09-30 · NCT07153796 · CT.gov ↗
What to watch
Phase 2Phase II Clinical Trial, Blinatumomab, Olverembatinib, Lymphoblastic Leukemia, Philadelphia Chromosome PositiveNot yet recruiting
Est. primary completion 2031-09-30 · NCT07178912 · CT.gov ↗
What to watch
December 2031 (1)
Phase 3Philadelphia Chromosome Negative B-cell Precursor Acute Lymphoblastic LeukemiaNot yet recruiting
Est. primary completion 2031-12-30 · NCT07223190 · CT.gov ↗
What to watch
2032 (3)
March 2032 (2)
Phase 1/2Leukemia, LymphomaRecruiting
Est. primary completion 2032-03 · NCT07294677 · CT.gov ↗
What to watch
Phase 3B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Central Nervous System Leukemia, Mixed Phenotype Acute Leukemia …Recruiting
Est. primary completion 2032-03-31 · NCT03959085 · CT.gov ↗
What to watch
December 2032 (1)
Phase 2Acute Lymphoid LeukemiaRecruiting
Est. primary completion 2032-12-31 · NCT05827549 · CT.gov ↗
What to watch
2033 (3)
March 2033 (1)
Phase 3B-Cell Acute Lymphoblastic LeukaemiaNot yet recruiting
Est. primary completion 2033-03-31 · NCT07476729 · CT.gov ↗
What to watch
June 2033 (1)
Phase 3Leukemia, Acute LymphoblasticRecruiting
Est. primary completion 2033-06 · NCT04307576 · CT.gov ↗
What to watch
September 2033 (1)
Phase 1/2Acute Lymphoblastic Leukemia, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive …Recruiting
Est. primary completion 2033-09-19 · NCT07387926 · CT.gov ↗
What to watch
2035 (1)
March 2035 (1)
Phase 2/3Acute Lymphoblastic LeukemiaRecruiting
Est. primary completion 2035-03-15 · NCT06860269 · CT.gov ↗
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.